Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection

Trial Profile

A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Paratek Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2016 Results of a pooled analysis (n=377) from this and other phase II trial (see profile 59200)presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 11 Apr 2016 According to a Paratek Pharmaceuticals media release, results of pooled analysis (n=377) from this and other phase II trial (see profile 59200) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
    • 11 Apr 2016 Results of pooled analysis (n=377) from this and other phase II trial (see profile 59200) published in the Paratek Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top